Please ensure Javascript is enabled for purposes of website accessibility

Sanofi and GlaxoSmithKline Join Forces to Develop a Coronavirus Vaccine

By Jim Crumly - Apr 14, 2020 at 4:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If the pharmaceutical giants are successful, their SARS-CoV-2 vaccine could be ready for use next year.

GlaxoSmithKline (GSK -0.80%) and Sanofi (SNY -0.88%), two European pharmaceutical companies that are leaders in vaccines for viral diseases, announced a collaboration to develop an adjuvanted vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. If the vaccine succeeds in clinical trials scheduled to start later this year, it could be available in the second half of 2021.

Sanofi will contribute a COVID-19 antigen that's based on its recombinant DNA technology. The company has produced an exact genetic match to proteins found on the surface of the virus, which are combined into the DNA of a baculovirus to create the antigen. Sanofi is using the technology in its quadrivalent flu vaccine Flublock; it obtained that product and the recombinant DNA platform through its acquisition of Protein Sciences in 2017.

Several coronavirus cells.

Image source: Getty Images.

GlaxoSmithKline will contribute its adjuvant technology to the vaccine. Adjuvants are chemical additives combined with vaccines that stimulate the body's immune system, causing it to produce a stronger response to the antigen. That means that a smaller amount of vaccine protein is required for each dose, so more vaccine doses can be produced in less time. GSK's adjuvant technology is a major reason for the success of its Shingrix shingles vaccine.

Both companies are taking multiple shots on the COVID-19 goal. Sanofi also makes hydroxychloroquine, a malaria drug that is being tested as a possible treatment for the disease. It has announced it will donate 100 million doses of it to 50 countries to be used in the fight against the pandemic. It's also working with Regeneron (REGN -1.32%) to test an existing arthritis drugKevzara, as a possible treatment, and has partnered with Translate Bio (TBIO) to develop a SAR-CoV-2 vaccine based on messenger RNA. GlaxoSmithKline is also contributing its adjuvant technology to COVID-19 vaccine candidates being developed by other companies, including Chinese biotech Clover Biopharmaceuticals and immunology specialist Vir Biotechnology (VIR -3.45%).

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$52.14 (-0.88%) $0.46
GSK Stock Quote
GSK
GSK
$43.35 (-0.80%) $0.35
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$594.42 (-1.32%) $-7.98
Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
TBIO
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$25.73 (-3.45%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.